ArticleAnnals of surgical oncology2025
Added Value of Fine-Needle Aspiration (FNA) or Breast Magnetic Resonance Imaging (MRI) as Part of the "Triple Test" to Assess Palpable Abnormalities on a Breast Exam With Negative Imaging Findings.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen a breast abnormality is palpated on a clinical breast exam in the setting of negative imaging (mammography and/or sonography), fine-needle aspiration (FNA) or magnetic resonance imaging (MRI) often is performed as part of the "triple test" to rule out malignancy. Because the negative predictive value (>97 %) of modern breast imaging is high, we hypothesized that additional evaluation with FNA and MRI adds little diagnostic value.
methodsThis study queried institutional databases to identify patients with negative breast imaging who underwent MRI or FNA for evaluation of a palpable breast abnormality on a clinical breast exam (2009-2023).
resultsFor 83 patients with 89 palpable abnormalities, the mean age was 48 years (interquartile range [IQR], 22.75 years). Two (2.4 %) of the patients had concurrent breast cancer. Of the 89 masses, 67 (75.3 %) underwent FNA only, 19 (21.3 %) underwent MRI only, and 3 (3.4 %) underwent FNA and MRI. The FNA findings were benign in 42 (60 %) cases, nondiagnostic in 25 (35.7 %) cases, atypical in 3 (4.3 %) cases, and malignant in 0 % cases. All MRIs were negative for an imaging correlate. For 12 masses, surgery was performed (11 excisional biopsies, 1 incisional biopsy), and all surgical pathology results were benign. During a median follow-up period of 6.6 years, no patients developed malignancy at the site of palpable abnormality, and six patients (7.2 %) developed breast cancer at other sites.
conclusionsFor women with palpable abnormalities and negative imaging, upgrade to malignancy with FNA or MRI was 0 %. We concluded that FNA or MRI as part of the "triple test" is a low-value intervention. Patients with a palpable breast abnormality may be safely followed with interval imaging.
Indexed as
Identifiers
40721967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.